Physician Prescriptions for ZOLL LifeVest Top 60,000
March 26 2012 - 6:00PM
Business Wire
ZOLL Medical Corporation (NASDAQ GS: ZOLL), a manufacturer of
medical devices and related software solutions, announced today
that more than 60,000 patients at high risk of sudden cardiac
arrest (SCA) have been prescribed the LifeVest® Wearable
Defibrillator.
The LifeVest is worn by patients at risk for SCA, providing
protection during their changing condition and while permanent SCA
risk has not been established. The LifeVest allows a patient’s
physician time to assess his or her long-term arrhythmic risk and
make appropriate plans.
The LifeVest is lightweight and easy to wear, allowing patients
to return to their activities of daily living, while having the
peace of mind that they are protected from SCA. The LifeVest
continuously monitors the patient’s heart and, if a
life-threatening heart rhythm is detected, the device delivers a
treatment shock to restore normal heart rhythm.
“The fact that over 60,000 patients have been prescribed the
LifeVest by their physicians demonstrates the ever increasing
adoption of this therapy as part of the treatment protocol to
protect patients at risk of SCA,” said Richard A. Packer, Chief
Executive Office of ZOLL. “The powerful result of partnering with
physicians to protect so many patients from SCA is that the life of
more than one patient per day is being saved worldwide by a ZOLL
LifeVest.”
The LifeVest is used for a wide range of patient conditions or
situations, including following a heart attack, before or after
bypass surgery or stent placement, as well as for those with
cardiomyopathy or congestive heart failure that places them at
particular risk.
The LifeVest is covered by most health plans in the United
States, including commercial, state, and federal plans.
For more information, go to www.zoll.com or call
1-800-543-3267.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices
and software solutions that help advance emergency care and save
lives, while increasing clinical and operational efficiencies. With
products for defibrillation and monitoring, circulation and CPR
feedback, data management, fluid resuscitation, and therapeutic
temperature management, ZOLL provides a comprehensive set of
technologies that help clinicians, EMS and fire professionals, and
lay rescuers treat victims needing resuscitation and critical
care.
A NASDAQ Global Select company and a three-time Forbes 100 Most
Trustworthy Company, ZOLL was designated in 2011 as one of Forbes
Top 100 Small Public Companies in America with annual revenues
under $1 billion. ZOLL develops and manufactures its products in
the United States, in California, Colorado, Illinois,
Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct
sales and service representatives, 1,100 business partners, and 200
independent representatives serve our customers in over 140
countries around the globe. For more information, visit
www.zoll.com.
Copyright © 2012 ZOLL Medical Corporation. All rights reserved.
269 Mill Road, Chelmsford, MA 01824-4105. LifeVest and ZOLL are
trademarks or registered trademarks of ZOLL Medical Corporation in
the United States and/or other countries. All product names are the
property of their respective owners.
Zoll (NASDAQ:ZOLL)
Historical Stock Chart
From Apr 2024 to May 2024
Zoll (NASDAQ:ZOLL)
Historical Stock Chart
From May 2023 to May 2024